Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.54 |
| ▸ | CNR2 | P34972 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | HTR7 | P34969 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13011475 | 0.90 | PTGER4 (0.58) | PTGER4ALDH1A1HPGDCNR1CNR2 | |
| SCHEMBL13011305 | 0.86 | CNR1 (0.58) | ALDH1A1CNR1NPY5R | |
| SCHEMBL13011809 | 0.84 | CNR1 (0.48) | PTGER4CNR1CNR2HTR7NPY5R | |
| SCHEMBL18028054 | 0.82 | TSHR (0.64) | ALDH1A1CNR1CNR2HTTHTR7 | |
| SCHEMBL4728886 | 0.80 | PTGER4 (0.67) | PTGER4ALDH1A1HPGDCNR2HTT | |
| SCHEMBL8803334 | 0.79 | ALDH1A1 (0.62) | ALDH1A1HPGDCNR2PARP1 | |
| SCHEMBL13635681 | 0.78 | CNR2 (0.54) | PTGER4CNR1CNR2HTR7 | |
| SCHEMBL10704403 | 0.77 | ABCB1 (0.60) | ALDH1A1CNR1CNR2 | |
| SCHEMBL13635125 | 0.76 | PARP1 (0.61) | ALDH1A1HPGDCNR2PARP1 | |
| SCHEMBL13011460 | 0.76 | OPRK1 (0.55) | PTGER4ALDH1A1CNR1CNR2NPY5R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2010-12-23 | — | — | US | disclosed |
| EP-2119704-A1 | ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2009-11-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324017-A1 | ACYLGUANIDINE DERIVATIVE | HTR5A, GRM5, HTR1E | PTGER4 1418/4885ALDH1A1 2104/4885HPGD 960/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.